Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in adults with plasma therapy-sensitive atypical hemolytic uremic syndrome
2008-006954-17Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: TMA event-free status. Started Feb 2009; status: completed.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2008-006954-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006954-17.